Chapters
Transcript
Episode notes
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
Introduction
00:00 • 3min
Sanofi's Takeout of Prometheus
03:19 • 2min
The Dice Lily Deal and the Industry Sentiment
05:01 • 2min
Sorepta's DMDG Therapy Conditional Approval
06:56 • 4min
The FDA Approves Sorepsis Gene Therapy
11:19 • 3min
Intercept for Nash Fibrosis: A Dynamic Plan
14:04 • 2min
Pfizer Gives Up Prometheus
15:41 • 3min
The Pros and Cons of Prometheus and Roy Van
18:34 • 4min
The Headwinds Affect Early Stage Investing
22:42 • 2min
The Unconstitutionality of IRA
24:26 • 4min
The Impact of the FTC Litigation on the Engines $27.8B Deal
28:12 • 2min
The FTC's View on Small Molecule Modality
30:24 • 4min
The FTC's Role in the Anti-Crescent Industry
34:23 • 2min
The Financial Relationship Between PBMs and Consulting Firms
36:06 • 2min
The Importance of Transparency in PBMs
37:52 • 4min
Leerink Partners With Baupost to Buy Back SVB Securities
41:45 • 2min
The SVB Meltdown: Bruce Leerink Back in the Fold
43:21 • 3min
Huntington's Disease: A Tough Disease to Address
45:53 • 2min
The Deerfield Deal and the Harvard Tech Transfer Office
47:27 • 2min
The Different Models of Accelerator Programs
49:50 • 4min
The Deerfield Model for Early Stage Ventures
53:21 • 2min
The Value of Interaction Between Industry and Academic Research
55:49 • 3min
The Rise of Venture Creation and Technology Transfer
58:40 • 2min